Scholar Rock SRRK Apitegromab — Research And Development Expense
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Scholar Rock in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Scholar Rock’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Scholar Rock's apitegromab — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Scholar Rock's apitegromab — research and development expense?
- Scholar Rock (SRRK) reported apitegromab — research and development expense of $20.26M in Q1 2026.
- How has Scholar Rock's apitegromab — research and development expense changed year-over-year?
- Scholar Rock's apitegromab — research and development expense increased by 5.0% year-over-year, from $19.3M to $20.26M.
- What does apitegromab — research and development expense mean?
- This metric represents the total operating costs directly attributable to the research, clinical development, and regulatory advancement of the Apitegromab product candidate. It captures the investment intensity required to progress this specific therapeutic asset through clinical trials and toward potential commercialization. Monitoring this expense helps investors assess the company's capital allocation strategy and the financial commitment dedicated to its primary pipeline asset.